Bayer suspends Trasylol sales

Bayer (FSE:BAY; BAY) will temporarily suspend worldwide marketing of Trasylol aprotinin following requests from regulatory agencies in Germany, Canada and the U.S. The move follows a warning from BAY to healthcare professionals two weeks ago after the Canadian BART trial was stopped because of higher mortality in patients given Trasylol. The investigator-sponsored trial in about 3,000 high-risk cardiac surgical patients was comparing Trasylol, epsilon-aminocaproic acid and tranexamic acid to reduce post-operative bleeding (See BioCentury Extra, Thursday, Oct. 25, 2007). ...